IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 63.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 56,691 shares of the company's stock after selling 97,911 shares during the period. Invesco Ltd. owned about 0.07% of IDEAYA Biosciences worth $1,457,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. FMR LLC increased its holdings in IDEAYA Biosciences by 2.6% in the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares in the last quarter. Vanguard Group Inc. raised its position in shares of IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after purchasing an additional 282,936 shares during the last quarter. Geode Capital Management LLC lifted its stake in IDEAYA Biosciences by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after buying an additional 43,226 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in IDEAYA Biosciences by 2.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock worth $49,891,000 after buying an additional 46,931 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in shares of IDEAYA Biosciences by 14.0% during the fourth quarter. Candriam S.C.A. now owns 1,071,825 shares of the company's stock valued at $27,546,000 after acquiring an additional 131,385 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IDYA. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens reaffirmed an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $53.58.

IDEAYA Biosciences Trading Down 13.3 %

IDYA stock traded down $2.72 during midday trading on Tuesday, hitting $17.75. 2,049,024 shares of the company's stock were exchanged, compared to its average volume of 978,649. The stock has a market capitalization of $1.55 billion, a PE ratio of -5.38 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The business has a 50-day simple moving average of $17.84 and a two-hundred day simple moving average of $22.89.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the firm earned ($0.53) earnings per share. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.